Department of Pharmaceutical Care Services, Princess Noorah Oncology Center (PNOC), King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs (MNGHA), P.O. Box 9515, Jeddah 21423, Saudi Arabia.
King Abdullah International Medical Research Center's (KAIMRC), Riyadh 11481, Saudi Arabia.
Med Sci (Basel). 2022 Nov 21;10(4):65. doi: 10.3390/medsci10040065.
Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic alterations including thyroid disorders, hyperglycemia, dyslipidemia, and adrenal insufficiency necessitate additional monitoring. The aim of this study was to assess the prevalence of monitoring errors and develop strategies for monitoring cancer patients who receive targeted therapies.
A retrospective chart review was used to assess the prevalence of monitoring errors of endocrinopathies among cancer patients who received targeted therapies over one year. All of the adult cancer patients diagnosed with a solid tumor who received targeted therapies were included. The primary outcome was to determine the prevalence of monitoring errors of endocrinopathies. The secondary outcomes were to assess the incidences of endocrinopathies and referral practice to endocrinology services.
A total of 128 adult patients with solid tumors were involved. The primary outcome revealed a total of 148 monitoring errors of endocrinopathies. Monitoring errors of the lipid profile and thyroid functions were the most common error types in 94% and 92.6% of the patients treated with novel targeted therapies, respectively. Subsequently, 57% of the monitoring errors in the blood glucose measures were identified. Targeted therapies caused 63 events of endocrinopathies, hyperglycemia in 32% of the patients, thyroid disorders in 15.6% of them and dyslipidemia in 1.5% of the patients.
Our study showed a high prevalence of monitoring errors among the cancer patients who received targeted therapies which led to endocrinopathies. It emphasizes the importance of adhering to monitoring strategies and following up on the appropriate referral process.
癌症治疗已逐渐演变为靶向分子疗法，其作用机制独特，而非非特异性细胞毒性化疗。然而，它们具有独特的安全问题。例如，内分泌疾病是指包括甲状腺疾病、高血糖、血脂异常和肾上腺功能不全在内的不利代谢改变，需要额外的监测。本研究旨在评估监测错误的发生率，并制定监测接受靶向治疗的癌症患者的策略。
采用回顾性病历审查，评估接受靶向治疗的癌症患者在一年内内分泌疾病监测错误的发生率。纳入所有接受靶向治疗的诊断为实体瘤的成年癌症患者。主要结局是确定内分泌疾病监测错误的发生率。次要结局是评估内分泌疾病的发生率和向内分泌科转介的实践。
共纳入 128 例成人实体瘤患者。主要结局显示，内分泌疾病监测错误共有 148 次。新型靶向治疗患者中，血脂谱和甲状腺功能监测错误分别是最常见的错误类型，占 94%和 92.6%。随后，57%的血糖监测错误被识别。靶向治疗导致 63 例内分泌疾病事件，其中 32%的患者出现高血糖，15.6%的患者出现甲状腺疾病，1.5%的患者出现血脂异常。
我们的研究显示，接受靶向治疗的癌症患者监测错误发生率较高，导致内分泌疾病。它强调了坚持监测策略和遵循适当的转介流程的重要性。
